Quote - "In a preclinical cell model of HBV infection, AS3...

Quote - "In a preclinical cell model of HBV infection, AS3 demonstrated statistically significant viral suppression compared to a control ASO."
Resonance Health ASO R&D Project leader, Dr. Sherif Boulos, commented: “Our positive data validates our ASO treatment strategy for chronic HBV, consolidates our intellectual property position, and supports continued investigation of AS3 in a preclinical animal model of disease. Shortly, we will commence a dosage study to test its effectiveness in a humanisedliver mouse strain. If successful, we aim to investigate if AS3 is effective in an HBV infection model using the same strain. Successful elimination of HBV will require a multi-drug approach, and because AS3 targets a human protein essential for viral growth, it is ideally suited to this purpose. In combination with other treatments, AS3 would also help to mitigate the emergence of drug resistant mutants, which is an important clinical consideration.”

This looks like a promising trial getting underway.